ストックスクリーナーアプリを入手
9.57
2.35%
-0.23
前日終値:
$9.80
開ける：
$9.9
24時間の取引高:
706.89K
Relative Volume:
0.35
時価総額：
$1.32B
収益：
$62.04M
当期純損益:
$-533.34M
株価収益率:
-2.4413
EPS:
-3.92
ネットキャッシュフロー:
$-473.07M
1週間 パフォーマンス:
-0.83%
1か月 パフォーマンス:
-8.16%
6か月 パフォーマンス:
+10.38%
1年 パフォーマンス:
-5.34%
1日の値動き範囲:
$9.51
$9.93
1週間の範囲:
$9.51
$9.98
52週間の値動き範囲:
$6.56
$14.45
Vir Biotechnology Inc Stock (VIR) Company Profile
名前
Vir Biotechnology Inc
セクター
電話
415-906-4324
住所
1800 OWENS STREET, SAN FRANCISCO, CA
VIR を他の銘柄と比較する
| 株式 | 価格 | 時価総額 | 収益 | 当期純利益 | 現金流量 | EPS |
|---|---|---|---|---|---|---|
VIR
Vir Biotechnology Inc
|
9.57 | 1.32B | 62.04M | -533.34M | -473.07M | -3.92 |
|
VRTX
Vertex Pharmaceuticals Inc
|
484.24 | 124.35B | 11.02B | -535.60M | -978.00M | -2.20 |
|
REGN
Regeneron Pharmaceuticals Inc
|
700.33 | 76.56B | 14.20B | 4.41B | 3.54B | 38.28 |
|
ARGX
Argen X Se Adr
|
644.48 | 39.16B | 1.86B | -40.29M | -1.28B | -0.85 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
250.59 | 32.44B | 2.25B | -278.16M | -42.59M | -2.17 |
|
BNTX
Biontech Se Adr
|
120.01 | 28.77B | 3.30B | -501.07M | 1.03B | -2.1146 |
Vir Biotechnology Inc Stock (VIR) Upgrades & Downgrades
| 日付 | アクション | アナリスト | 評価の変更 |
|---|---|---|---|
| 2024-01-29 | ダウングレード | JP Morgan | Overweight → Neutral |
| 2023-09-08 | ダウングレード | BofA Securities | Buy → Neutral |
| 2023-03-06 | アップグレード | JP Morgan | Neutral → Overweight |
| 2023-02-21 | アップグレード | Goldman | Neutral → Buy |
| 2023-01-27 | アップグレード | Morgan Stanley | Underweight → Equal-Weight |
| 2022-09-14 | 開始されました | SVB Leerink | Outperform |
| 2022-09-09 | 開始されました | Morgan Stanley | Underweight |
| 2022-03-03 | アップグレード | Robert W. Baird | Underperform → Neutral |
| 2021-12-21 | ダウングレード | Robert W. Baird | Neutral → Underperform |
| 2021-10-25 | アップグレード | JP Morgan | Underweight → Neutral |
| 2021-09-22 | ダウングレード | Goldman | Buy → Neutral |
| 2021-06-04 | 再開されました | Robert W. Baird | Neutral |
| 2021-01-27 | ダウングレード | JP Morgan | Neutral → Underweight |
| 2021-01-20 | 繰り返されました | H.C. Wainwright | Buy |
| 2020-10-05 | 開始されました | BofA Securities | Buy |
| 2020-09-14 | アップグレード | Goldman | Neutral → Buy |
| 2020-09-11 | アップグレード | JP Morgan | Underweight → Neutral |
| 2020-08-20 | 開始されました | Needham | Buy |
| 2020-03-19 | ダウングレード | JP Morgan | Neutral → Underweight |
| 2020-03-13 | ダウングレード | Goldman | Buy → Neutral |
| 2020-02-27 | ダウングレード | Robert W. Baird | Neutral → Underperform |
| 2020-02-04 | ダウングレード | JP Morgan | Overweight → Neutral |
| 2019-11-14 | 開始されました | Robert W. Baird | Neutral |
| 2019-11-05 | 開始されました | Barclays | Overweight |
| 2019-11-05 | 開始されました | Cowen | Outperform |
| 2019-11-05 | 開始されました | Goldman | Buy |
| 2019-11-05 | 開始されました | JP Morgan | Overweight |
すべてを表示
Vir Biotechnology Inc (VIR) 最新ニュース
(VIR) Trading Advice - Stock Traders Daily
Vir Biotechnology to Participate in TD Cowen 45th Annual Health Care Conference - BioSpace
Vir Biotechnology director George Scangos sells $107,575 in stock By Investing.com - Investing.com South Africa
Vir Biotechnology director George Scangos sells $107,575 in stock - Investing.com
Will Vir Biotechnology Reveal New Strategic Initiatives? Key Conference Appearance Ahead - StockTitan
Vir Biotechnology, Inc. (NASDAQ:VIR) Shares Sold by Empowered Funds LLC - MarketBeat
Brent Sabatini Sells 1,562 Shares of Vir Biotechnology, Inc. (NASDAQ:VIR) Stock - MarketBeat
Vir Biotechnology SVP sells shares for $14,291 - MSN
Xencor, Inc. Enters License Agreement for Use of Xtend™ XmAb® Antibody Technology in Investigational Antibodies to Treat Covid-19 with Vir Biotechnology - Marketscreener.com
Vir Biotechnology (NASDAQ:VIR) Shares Down 4.8%Here's Why - MarketBeat
Vir Biotechnology SVP sells shares for $14,291 By Investing.com - Investing.com Nigeria
Vir Biotechnology Officer Sells Shares to Cover Tax Obligations - TradingView
abrdn plc Buys Shares of 363,161 Vir Biotechnology, Inc. (NASDAQ:VIR) - MarketBeat
Vir Biotechnology Sets Stage for Major Corporate Strategy Reveal with Q4 Earnings - StockTitan
Vir Biotechnology, Inc. (NASDAQ:VIR) Receives Average Recommendation of "Moderate Buy" from Brokerages - MarketBeat
(VIR) Pivots Trading Plans and Risk Controls - Stock Traders Daily
Vir Biotechnology price target raised to $14 from $10 at JPMorgan - MSN
FY2029 EPS Estimate for Vir Biotechnology Lowered by Analyst - MarketBeat
After a year of 7.8% returns, Vir Biotechnology, Inc.'s (NASDAQ:VIR) share price drop last week may have less of an impact on institutional investors - Simply Wall St
HC Wainwright Reiterates Buy Rating for Vir Biotechnology (NASDAQ:VIR) - MarketBeat
Vir Biotechnology, Inc. (NASDAQ:VIR) Short Interest Update - MarketBeat
Vir Biotechnology appoints new Chief Technical Officer By Investing.com - Investing.com Australia
Vir Biotechnology Inc. (VIR) Stock Overview and Recent Developments – Market - HPBL
Vir Biotechnology Shares Surge After Opening Higher: A Market Overview – Market - HPBL
Vir Biotechnology, Inc. Announces Executive Changes -January 30, 2025 at 07:51 am EST - Marketscreener.com
Vir Biotechnology appoints new Chief Technical Officer - Investing.com
Vir Biotechnology Announces Leadership Change in 2025 - TipRanks
Vir Biotechnology Inc. (VIR) Announces CTO Departure - StreetInsider.com
Trading (VIR) With Integrated Risk Controls - Stock Traders Daily
Vir Biotechnology Phase 1 Data on Dual-Masked T-Cell Engagers (TCEs) – Market - HPBL
Vir Biotechnology (NASDAQ:VIR) Shares Down 3.8%Should You Sell? - MarketBeat
Vir Biotechnology (NASDAQ:VIR) Shares Up 6.3%What's Next? - MarketBeat
Why Vir Biotechnology, Inc. (VIR) Is Skyrocketing Now - Insider Monkey
Hepatitis B Virus Infection Clinical and Non-Clinical Studies, - openPR
Vir, Sana gain new modality POC: BioCentury’s Clinical Report - BioCentury
JP Morgan Week 2025 – Marianne De Backer - pharmaphorum
What is Leerink Partnrs’ Forecast for VIR Q1 Earnings? - Defense World
Vir Biotechnology Inc (VIR) 財務データ
収益
当期純利益
現金流量
EPS
0.27%
3.05%
大文字化:
|
ボリューム (24 時間):